Historical perspective of cell-cell fusion in cancer initiation and progression

Critical Reviews in Oncogenesis

Volumn 18, Issue 1-2, 2013, Pages 1-18

  Parris, George E ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aneuploid; Boveri; Cell fusion; Endoreduplication; Hybrid; Leukocyte; Macrophage; Metastasis; Mutation; Tetraploid; Virus

Indexed keywords

CADHERIN; CARCINOGEN; CELL SURFACE PROTEIN; INTEGRIN;

ANEUPLOIDY; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CATALYST; CELL CELL FUSION; CELL CLONE; CELL FUNCTION; CELL FUSION; CELL HYBRIDIZATION; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CYTOGENETICS; ENDOREDUPLICATION; EXOSOME; GLYCOSYLATION; HISTORY OF MEDICINE; HUMAN; HYBRID CELL; KARYOTYPE; LEUKOCYTE; LYMPH NODE; MACROPHAGE; METASTASIS; MUTATION; NATURAL SELECTION; NONHUMAN; PRIORITY JOURNAL; PROGENY; REPRODUCTION; SOMATIC CELL; TETRAPLOIDY; THERAPY; TUMOR MICROENVIRONMENT; WART VIRUS;

ANEUPLOIDY; CELL FUSION; CELL TRANSFORMATION, NEOPLASTIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYBRID CELLS; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; SELECTION, GENETIC;

EID: 84875328077     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v18.i1-2.20     Document Type: Article

References (259)

1. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. Suppression of malignancy by cell fusion. Nature. 1969;223(5204):363-8.
2. King RW. When 2+2=5: the origins and fates of aneuploid and tetraploid cells. Biochim Biophys Acta. 2008;1786(1):4-14.
3. Schwerer MJ, Hemmer J, Kraft K, Maier H, Moller P, Barth TF. Endoreduplication in conjunction with tumor progression in an aneuploid laryngeal squamous cell carcinoma. Virchows Arch. 2003;443(1):98-103.
4. Wilsker D, Chung JH, Bunz F. Chk1 suppresses bypass of mitosis and tetraploidization in p53-deficient cancer cells. Cell Cycle. 2012;11(8):1,564-72.
5. Deneberg S. Epigenetics in myeloid malignancies. Methods Mol Biol. 2012;863:119-37.
6. Matulic M, Paradzik M, Cicin-Sain L, Kapitanovic S, Dubravcic K, Batinic D, Antica M. Ikaros family transcription factors in chronic and acute leukemia. Am J Hematol. 2009;84(6):375-7.
7. Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell. 1995;83(2):289-99.
8. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144-7.
9. Holz-Schietinger C, Matje DM, Flexer Harrison M, Reich NO. Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation. J Biol Chem. 2011; 286(48):41,479-88.
10. Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H, Luo JL, Patel DJ, Allis CD. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature. 2009;459(7248):847-51.
11. Fan T, Schmidtmann A, Xi S, Briones V, Zhu H, Suh HC, Gooya J, Keller JR, Xu H, Roayaei J, Anver M, Ruscetti S, Muegge K. DNA hypomethylation caused by Lsh deletion promotes erythroleukemia development. Epigenetics. 2008;3(3):134-42.
12. Niitsu N, Hayashi Y, Sugita K, Honma Y. Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3. Br J Haematol. 2001;112(2):315-26.
13. Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol.2012;39(1):97-108.
14. Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci. 2008;121 Suppl 1:1-84.
15. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol. 2009;10(7):478-87.
16. Ried T. Homage to Theodor Boveri (1862-1915): Boveri's theory of cancer as a disease of the chromosomes, and the landscape of genomic imbalances in human carcinomas. Environ Mol Mutagen. 2009;50(8):593-601.
17. Metcalf MM. Boveri on cancer. Science. 1926;64(1664):499-500.
18. Wood FC, Schneider A. Boveri on cancer. Science. 1927;65(1671):14-15.
19. Anonymous. Mutation and the origin of cancer. Cal West Med. 1937;46(1):65-6.
20. Sturtevant AH, Bridges CB, Morgan TH. The spatial relations of genes. Proc Natl Acad Sci U S A. 1919;5(5):168-73.
21. Morgan TH, Sturtevant AH, Bridge CB. The Evidence for the Linear Order of the Genes. Proc Natl Acad Sci U S A. 1920;6(4):162-4.
22. Sturtevant AH. Linkage variation and chromosome maps. Proc Natl Acad Sci U S A. 1921;7(7):181-3.
23. Muller HJ. Artificial transmutation of the gene. Science. 1927;66(1699):84-7.
24. Calabrese EJ. Muller's Nobel lecture on dose-response for ionizing radiation: ideology or science? Arch Toxicol. 2012;126(1):1-4.
25. Abdulreda MH, Bhalla A, Rico F, Berggren PO, Chapman ER, Moy VT. Pulling force generated by interacting SNAREs facilitates membrane hemifusion. Integr Biol (Camb). 2009;1(4):301-10.
26. Miller JA, Miller EC. Metabolic activation and reactivity of chemical carcinogens. Mutat Res.1975;33(1 Spec No):25-6.
27. Miller JA, Miller EC. The metabolic activation and nucleic acid adducts of naturally-occurring carcinogens: recent results with ethyl carbamate and the spice flavors safrole and estragole. Br J Cancer. 1983;48(1):1-15.
28. Miller JA, Miller EC. Some historical aspects of N-aryl carcinogens and their metabolic activation. Environ Health Perspect. 1983;49:3-12.
29. Miller JA, Miller EC. The metabolic activation of carcinogenic aromatic amines and amides. Prog Exp Tumor Res. 1969;11:273-301.
30. Miller JA, Miller EC. Carcinogens occurring naturally in foods. Fed Proc. 1976;35(6):1,316-21.
31. Wakonig R. Aneuploidy in neoplasia--cause or result. Can J Genet Cytol. 1960;2:344-56.
32. Li R, Sonik A, Stindl R, Rasnick D, Duesberg P. Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. Proc Natl Acad Sci U S A. 2000;97(7):3,236-41.
33. Li R, Yerganian G, Duesberg P, Kraemer A, Willer A, Rausch C, Hehlmann R. Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells. Proc Natl Acad Sci U S A. 1997;94(26):14,506-11.
34. asnick D, Duesberg PH. How aneuploidy affects metabolic control and causes cancer. Biochem J. 1999;340 (Pt 3):621-30.
35. Gagos S, Iliopoulos D, Tseleni-Balafouta S, Agapitos M, Antachopoulos C, Kostakis A, Karayannakos P, Skalkeas G. Cell senescence and a mechanism of clonal evolution leading to continuous cell proliferation, loss of heterozygosity, and tumor heterogeneity: studies on two immortal colon cancer cell lines. Cancer Genet Cytogenet. 1996;90(2):157-65.
36. Wolman SR. Karyotypic progression in human tumors. Cancer Metastasis Rev. 1983;2(3):257-93.
37. Barrett JC. Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect. 1993;100:9-20.
38. Duesberg P. Chromosomal chaos and cancer. Sci Am. 2007;296(5):52-9.
39. Duesberg P, Li R, Fabarius A, Hehlmann R. Aneuploidy and cancer: from correlation to causation. Contrib Microbiol. 2006;13:16-44.
40. Duesberg P, Li R, Fabarius A, Hehlmann R. The chromosomal basis of cancer. Cell Oncol. 2005;27(5-6):293-318.
41. Nicholson JM, Duesberg P. On the karyotypic origin and evolution of cancer cells. Cancer Genet Cytogenet. 2009;194(2):96-110.
42. Duesberg P, Mandrioli D, McCormack A, Nicholson JM. Is carcinogenesis a form of speciation? Cell Cycle. 2011;10(13):2,100-14.
43. Duesberg P, Rasnick D. Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motil Cytoskeleton. 2000;47(2):81-107.
44. Duesberg P, Li R, Rasnick D, Rausch C, Willer A, Kraemer A, Yerganian G, Hehlmann R. Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet. 2000;119(2):83-93.
45. Hardy PA, Zacharias H. Reappraisal of the Hansemann-Boveri hypothesis on the origin of tumors. Cell Biol Int. 2005;29(12):983-92.
46. Parris GE. Clinically significant cancer evolves from transient mutated and/or aneuploid neoplasia by cell fusion to form unstable syncytia that give rise to ecologically viable parasite species. Med Hypotheses. 2005;65(5):846-50.
47. Parris GE. The cell clone ecology hypothesis and the cell fusion model of cancer progression and metastasis: history and experimental support. Med Hypotheses. 2006;66(1):76-83.
48. Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist Updat. 2007;10(1-2):51-8.
49. Duesberg P, Rasnick D, Li R, Winters L, Rausch C, Hehlmann R. How aneuploidy may cause cancer and genetic instability. Anticancer Res. 1999;19(6A):4,887-4906.
50. Foijer F. CINister thoughts. Biochem Soc Trans. 2010 Dec;38(6):1,715-21.
51. Gagos S, Irminger-Finger I. Chromosome instability in neoplasia: chaotic roots to continuous growth. Int J Biochem Cell Biol. 2005;37(5):1,014-33.
52. Goepfert TM, Moreno-Smith M, Edwards DG, Pathak S, Medina D, Brinkley WR. Loss of chromosomal integrity drives rat mammary tumorigenesis. Int J Cancer. 2007;120(5):985-94.
53. Heng HH, Bremer SW, Stevens J, Ye KJ, Miller F, Liu G, Ye CJ. Cancer progression by non-clonal chromosome aberrations. J Cell Biochem. 2006;98(6):1424-35.
54. Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ. Evolutionary mechanisms and diversity in cancer. Adv Cancer Res. 2011;112:217-53.
55. Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky MA, Ye CJ. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol. 2006;208(2):461-72.
56. Klein A, Zang KD, Steudel WI, Urbschat S. Different mechanisms of mitotic instability in cancer cell lines. Int J Oncol. 2006;29(6):1,389-96.
57. Matzke MA, Mette MF, Kanno T, Matzke AJ. Does the intrinsic instability of aneuploid genomes have a causal role in cancer? Trends Genet. 2003;19(5):253-6.
58. Padilla-Nash HM, Hathcock K, McNeil NE, Mack D, Hoeppner D, Ravin R, Knutsen T, Yonescu R, Wangsa D, Dorritie K, Barenboim L, Hu Y, Ried T. Spontaneous transformation of murine epithelial cells requires the early acquisition of specific chromosomal aneuploidies and genomic imbalances. Genes Chromosomes Cancer. 2012;51(4):353-74.
59. Thompson SL, Bakhoum SF, Compton DA. Mechanisms of Chromosomal Instability. Curr Biol. 2010;20(6):R285-R295.
60. Ye CJ, Liu G, Bremer SW, Heng HH. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res. 2007;118(2-4):237-46.
61. Yuen KW, Desai A. The wages of CIN. J Cell Biol. 2008;180(4):661-3.
62. Parris GE. Chromosomal instability (CIN) leads to clone extinction, not cancer. Med Hypotheses. 2008;71(6):983.
63. Baverstock K. Muller's ratchet hypothesis. Lancet. 2004;364(9441):1,213.
64. Andersson DI, Hughes D. Muller's ratchet decreases fitness of a DNA-based microbe. Proc Natl Acad Sci U S A. 1996;93(2):906-7.
65. Chao L. Fitness of RNA virus decreased by Muller's ratchet. Nature. 1990;348(6300):454-5.
66. Charlesworth B, Charlesworth D. The degeneration of Y chromosomes. Philos Trans R Soc Lond B Biol Sci. 2000;355(1403):1,563-72.
67. Engelstadter J. Muller's ratchet and the degeneration of Y chromosomes: a simulation study. Genetics. 2008;180(2):957-67.
68. Fontanari JF, Colato A, Howard RS. Mutation accumulation in growing asexual lineages. Phys Rev Lett. 2003;91(21):218,101.
69. Gordo I, Campos PR. Sex and deleterious mutations. Genetics. 2008;179(1):621-6.
70. Haigh J. The accumulation of deleterious genes in a population--Muller's Ratchet. Theor Popul Biol. 1978;14(2):251-67.
71. Janko K, Drozd P, Eisner J. Do clones degenerate over time? Explaining the genetic variability of asexuals through population genetic models. Biol Direct. 2011;6:17-42.
72. Keightley PD, Otto SP. Interference among deleterious mutations favours sex and recombination in finite populations. Nature. 2006;443(7107):89-92.
73. Loewe L, Cutter AD. On the potential for extinction by Muller's ratchet in Caenorhabditis elegans. BMC Evol Biol. 2008;8:125-38.
74. Maia LP. Analytical results on Muller's ratchet effect in growing populations. Phys Rev E Stat Nonlin Soft Matter Phys. 2009;79(3 Pt 1):032903.
75. Som C, Bagheri HC, Reyer HU. Mutation accumulation and fitness effects in hybridogenetic populations: a comparison to sexual and asexual systems. BMC Evol Biol. 2007;7:80-91.
76. Yuste E, Sanchez-Palomino S, Casado C, Domingo E, Lopez-Galindez C. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol. 1999;73(4):2,745-51.
77. Andersson SG, Karlberg O, Canback B, Kurland CG. On the origin of mitochondria: a genomics perspective. Philos Trans R Soc Lond B Biol Sci. 2003;358(1429):165-77.
78. Dunning Hotopp JC. Horizontal gene transfer between bacteria and animals. Trends Genet. 2011;27(4):157-63.
79. Keeling PJ. Functional and ecological impacts of horizontal gene transfer in eukaryotes. Curr Opin Genet Dev. 2009;19(6):613-9.
80. Keeling PJ. Role of horizontal gene transfer in the evolution of photosynthetic eukaryotes and their plastids. Methods Mol Biol. 2009;532:501-15.
81. Lind PA, Tobin C, Berg OG, Kurland CG, Andersson DI. Compensatory gene amplification restores fitness after inter-species gene replacements. Mol Microbiol. 2010;75(5):1,078-89.
82. McDaniel LD, Young E, Delaney J, Ruhnau F, Ritchie KB, Paul JH. High frequency of horizontal gene transfer in the oceans. Science. 2010;330(6000):50.
83. Paul JH. Prophages in marine bacteria: dangerous molecular time bombs or the key to survival in the seas? ISME J. 2008;2(6):579-89.
84. Schaack S, Gilbert C, Feschotte C. Promiscuous DNA: horizontal transfer of transposable elements and why it matters for eukaryotic evolution. Trends Ecol Evol. 2010;25(9):537-46.
85. Treangen TJ, Rocha EP. Horizontal transfer, not duplication, drives the expansion of protein families in prokaryotes. PLoS Genet. 2011;7(1):e1001284.
86. Bergstrom CT, McElhany P, Real LA. Transmission bottlenecks as determinants of virulence in rapidly evolving pathogens. Proc Natl Acad Sci U S A. 1999;96(9):5,095-100.
87. Novella IS, Elena SF, Moya A, Domingo E, Holland JJ. Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. J Virol. 1995;69(5):2,869-72.
88. Bignold LP. Aneuploidy as a counter to "Muller's ratchet" in cancer cells. Cancer Genet Cytogenet. 2007;178(2):173-4.
89. Soppa J. Ploidy and gene conversion in Archaea. Biochem Soc Trans. 2011;39(1):150-4.
90. Illidge TM, Cragg MS, Fringes B, Olive P, Erenpreisa JA. Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage. Cell Biol Int. 2000;24(9):621-33.
91. Ivanov A, Cragg MS, Erenpreisa J, Emzinsh D, Lukman H, Illidge TM. Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. J Cell Sci. 2003;116(Pt 20):4,095-106.
92. Puig PE, Guilly MN, Bouchot A, Droin N, Cathelin D, Bouyer F, Favier L, Ghiringhelli F, Kroemer G, Solary E, Martin F, Chauffert B. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 2008, 32(9):1,031-43.
93. Berman J, Hadany L. Does stress induce (para)sex? Implications for Candida albicans evolution. Trends Genet. 2012;28(5):197-203.
94. Klingelhutz AJ. The roles of telomeres and telomerase in cellular immortalization and the development of cancer. Anticancer Res. 1999;19(6A):4,823-30.
95. Naveilhan P, Baudet C, Jabbour W, Wion D. A theory that may explain the Hayflick limit--a means to delete one copy of a repeating sequence during each cell cycle in certain human cells such as fibroblasts. Mech Ageing Dev. 1994;75(3):205-13.
96. Rubin H. Multistage carcinogenesis in cell culture. Dev Biol. (Basel) 2001;106:61-6; discussion 67, 143-60.
97. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1(1):72-6.
98. Bremermann HJ. Theory of spontaneous cell fusion. Sexuality in cell populations as an evolutionarily stable strategy. Applications to immunology and cancer. J Theor Biol. 1979;76(3):311-34.
99. Dezentje DA, Arking DE, Kortenhorst MS, West K, Chakravarti A, Kern SE. Hybrids of aneuploid human cancer cells permit complementation of simple and complex cancer defects. Cancer Biol Ther. 2009;8(4):347-55.
100. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev. 2007;17(2):157-62.
101. Ho CC, Hau PM, Marxer M, Poon RY. The requirement of p53 for maintaining chromosomal stability during tetraploidization. Oncotarget. 2010;1(7):583-95.
102. Goldenberg DM, Gotz H. On the 'human' nature of highly malignant heterotransplantable tumors of human origin. Eur J Cancer. 1968;4(5):547-8.
103. Gotz H, Goldenberg DM. Antigenic characterization of a heterotransplanted human tumour, GW-127. Experientia. 1968;24(9):957-8.
104. Haemmerli G, Schmid W, Lindemann J. Cytogenetic and antigenic properties of GW-127, a heterologously transplantable tumor. Eur J Cancer. 1968;4(3):279-85.
105. Goldenberg DM. [On the progression of malignity: a hypothesis]. Klin Wochenschr. 1968;46(16):898-9.
106. Harris H. The use of cell fusion in the analysis of gene action. Proc R Soc Lond B Biol Sci. 1970;176(44):315-7.
107. Harris H. The expression of genetic information by somatic cell nuclei. J Gen Microbiol. 1970;63(3):vi.
108. Harris H. Cell fusion and the analysis of malignancy. Proc R Soc Lond B Biol Sci. 1971;179(54):1-20.
109. Harris H, Bregula U, Klein G. The analysis of malignancy by cell fusion. II. Hybrids between Ehrlich cells and normal diploid cells. J Cell Sci. 1971;8(3):673-80.
110. Harris H, Wiener F, Klein G. The analysis of malignancy by cell fusion. 3. Hybrids between diploid fibroblasts and other tumour cells. J Cell Sci. 1971;8(3):681-92.
111. Klein G, Bregula U, Wiener F, Harris H. The analysis of malignancy by cell fusion. I. Hybrids between tumour cells and L cell derivatives. J Cell Sci. 1971;8(3):659-72.
112. Wiener F, Fenyo EM, Klein G, Harris H. Fusion of tumour cells with host cells. Nat New Biol. 1972;238(83):155-9.
113. Duncan AW, Hickey RD, Paulk NK, Culberson AJ, Olson SB, Finegold MJ, Grompe M. Ploidy reductions in murine fusion-derived hepatocytes. PLoS Genet. 2009;5(2):e1000385.
114. Duncan AW, Taylor MH, Hickey RD, Hanlon Newell AE, Lenzi ML, Olson SB, Finegold MJ, Grompe M. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature. 2010;467(7316):707-10.
115. Erenpreisa J, Salmina K, Huna A, Kosmacek EA, Cragg M, Ianzini F, Anisimov A. Polyploid tumour cells elicit para-diploid progeny through de-polyploidising divisions and regulated autophagic degradation. Cell Biol Int. 2011;35(7):687-95.
116. Rajaraman R, Rajaraman MM, Rajaraman SR, Guernsey DL. Neosis--a paradigm of self-renewal in cancer. Cell Biol Int. 2005;29(12):1,084-97.
117. Sundaram M, Guernsey DL, Rajaraman MM, Rajaraman R. Neosis: a novel type of cell division in cancer. Cancer Biol Ther. 2004;3(2):207-18.
118. Evans EP, Burtenshaw MD, Brown BB, Hennion R, Harris H. The analysis of malignancy by cell fusion. IX. Re-examination and clarification of the cytogenetic problem. J Cell Sci. 1982;56:113-30.
119. Harris H. The analysis of malignancy by cell fusion: the position in 1988. Cancer Res. 1988;48(12):3,302-6.
120. Harris H. Some thoughts about genetics, differentiation, and malignancy. Somatic Cell Genet. 1979;5(6):923-30.
121. Harris H. Some recent progress in the analysis of malignancy by cell fusion. Ciba Found Symp. 1979;(66):311-33.
122. Jonasson J, Harris H. The analysis of malignancy by cell fusion. VIII. Evidence for the intervention of an extra-chromosomal element. J Cell Sci. 1977;24:255-63.
123. Jonasson J, Povey S, Harris H. The analysis of malignancy by cell fusion. VII. Cytogenetic analysis of hybrids between malignant and diploid cells and of tumours derived from them. J Cell Sci. 1977;24:217-54.
124. Klein G, Friberg S Jr, Wiener F, Harris H. Hybrid cells derived from fusion of TA3-Ha ascites carcinoma with normal fibroblasts. 1. Malignancy, karyotype, and formation of isoantigenic variants. J Natl Cancer Inst. 1973;50(5):1,259-68.
125. Wiener F, Klein G, Harris H. The analysis of malignancy by cell fusion. VI. Hybrids between different tumour cells. J Cell Sci. 1974;16(1):189-98.
126. Wiener F, Klein G, Harris H. The analysis of malignancy by cell fusion. V. Further evidence of the ability of normal diploid cells to suppress malignancy. J Cell Sci. 1974;15(1):177-83.
127. Wiener F, Klein G, Harris H. The analysis of malignancy by cell fusion. IV. Hybrid between tumour cells and a malignant L cell derivative. J Cell Sci. 1973;12(1):253-61.
128. Stoler A, Bouck N. Identification of a single chromosome in the normal human genome essential for suppression of hamster cell transformation. Proc Natl Acad Sci U S A. 1985;82(2):570-4.
129. Goldenberg DM, Bhan RD, Pavia RA. In vivo human-hamster somatic cell fusion indicated by glucose 6-phosphate dehydrogenase and lactate dehydrogenase profiles. Cancer Res. 1971;31(8):1,148-52.
130. Goldenberg DM, Pavia RA, Tsao MC. In vivo hybridisation of human tumour and normal hamster cells. Nature. 1974;250(5468):649-51.
131. Goldenberg DM, Pavia RA. Oncogenesis by interspecific interaction of malignant murine and non-malignant hamster cells in vitro. Int J Cancer. 1975;15(2):282-300.
132. Goldenberg DM, Pavia RA. In vivo horizontal oncogenesis by a human tumor in nude mice. Proc Natl Acad Sci U S A. 1982;79(7):2,389-92.
133. Goldenberg DM, Pavia RA. Malignant potential of murine stromal cells after transplantation of human tumors into nude mice. Science. 1981;212(4490):65-7.
134. Goldenberg DM, Pavia RA. Horizontal transmission of malignant conditions rediscovered. N Engl J Med. 1981;305(5):283-4.
135. Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, Berroa Garcia LY, Ried T, Loo M, Chang CH, Gold DV. Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells In Vivo. Int J Cancer. 2012;131(1):49-58.
136. Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, Berroa Garcia LY, Ried T, Loo M, Chang CH, Gold DV. Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. Int J Cancer. 2012;131(1):49-58.[Q1]
137. Kakpakova ES, Malahova EM, Massino JS, Pogosianz HE. Somatic cell hybrids of the Djungarian hamster: malignancy and evolution of the karyotype. Carcinogenesis. 1980; 1(7):539-45.
138. Larizza L, Tenchini ML, Mottura A, De Carli L, Colombi M, Barlati S. Expression of transformation markers and suppression of tumorigenicity in human cell hybrids. Eur J Cancer Clin Oncol. 1982;18(9):845-51.
139. Larizza L, Schirrmacher V, Pfluger E. Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage. J Exp Med. 1984;160(5):1,579-84.
140. Larizza L, Schirrmacher V, Graf L, Pfluger E, Peres-Martinez M, Stohr M. Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage. Int J Cancer. 1984;34(5):699-707.
141. Larizza L, Schirrmacher V. Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants. Cancer Metastasis Rev. 1984;3(3):193-222.
142. Pawelek JM. Melanoma as a macrophage/melanocyte hybrid and the symbiotic nature of eukaryotic cells. Melanoma Res. 1993;3(1):75-6.
143. Rachkovsky M, Sodi S, Chakraborty A, Avissar Y, Bolognia J, McNiff JM, Platt J, Bermudes D, Pawelek J. Melanoma x macrophage hybrids with enhanced metastatic potential. Clin Exp Metastasis. 1998;16(4):299-312.
144. Chakraborty AK, Pawelek J, Ikeda Y, Miyoshi E, Kolesnikova N, Funasaka Y, Ichihashi M, Taniguchi N. Fusion hybrids with macrophage and melanoma cells up-regulate N-acetylglucosaminyltransferase V, beta1-6 branching, and metastasis. Cell Growth Differ. 2001;12(12):623-30.
145. Chakraborty AK, Pawelek JM. GnT-V, macrophage and cancer metastasis: a common link. Clin Exp Metastasis. 2003;20(4):365-73.
146. Chakraborty AK, Sousa Jde F, Chakraborty D, Funasaka Y, Bhattacharya M, Chatterjee A, Pawelek J. GnT-V expression and metastatic phenotypes in macrophage-melanoma fusion hybrids is down-regulated by 5-Aza-dC: evidence for methylation sensitive, extragenic regulation of GnT-V transcription. Gene. 2006;374:166-73.
147. Pawelek JM, Chakraborty AK, Rachkovsky ML, Orlow SJ, Bolognia JL, Sodi SA. Altered N-glycosylation in macrophage x melanoma fusion hybrids. Cell Mol Biol (Noisy-le-grand). 1999;45(7):1,011-27.
148. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241-319.
149. Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol. 1997;50(2):57-71.
150. Sperandio M. Selectins and glycosyltransferases in leukocyte rolling in vivo. FEBS J. 2006;273(19):4,377-89.
151. Sperandio M, Gleissner CA, Ley K. Glycosylation in immune cell trafficking. Immunol Rev. 2009;230(1):97-113.
152. Gu J, Taniguchi N. Potential of N-glycan in cell adhesion and migration as either a positive or negative regulator. Cell Adh Migr. 2008;2(4):243-5.
153. Guo HB, Johnson H, Randolph M, Pierce M. Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. J Biol Chem. 2009;284(50):34,986-97.
154. Liwosz A, Lei T, Kukuruzinska MA. N-glycosylation affects the molecular organization and stability of E-cadherin junctions. J Biol Chem. 2006;281(32):23,138-49.
155. Pinho SS, Reis CA, Paredes J, Magalhaes AM, Ferreira AC, Figueiredo J, Xiaogang W, Carneiro F, Gartner F, Seruca R. The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum Mol Genet. 2009;18(14):2,599-608.
156. Przybylo M, Hoja-Lukowicz D, Litynska A, Laidler P. Different glycosylation of cadherins from human bladder non-malignant and cancer cell lines. Cancer Cell Int. 2002;2:6-11.
157. Zhao Y, Sato Y, Isaji T, Fukuda T, Matsumoto A, Miyoshi E, Gu J, Taniguchi N. Branched N-glycans regulate the biological functions of integrins and cadherins. FEBS J. 2008;275(9):1,939-48.
158. Isaji T, Kariya Y, Xu Q, Fukuda T, Taniguchi N, Gu J. Functional roles of the bisecting GlcNAc in integrin-mediated cell adhesion. Methods Enzymol. 2010;480:445-59.
159. Sato Y, Isaji T, Tajiri M, Yoshida-Yamamoto S, Yoshinaka T, Somehara T, Fukuda T, Wada Y, Gu J. An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III. J Biol Chem. 2009;284(18):11,873-81.
160. Yang X, Li J, Geng M. N-acetylglucosaminyltransferase V modifies TrKA protein, regulates the receptor function. Cell Mol Neurobiol. 2008;28(5):663-70.
161. Pawelek J, Chakraborty A, Lazova R, Yilmaz Y, Cooper D, Brash D, Handerson T. Co-opting macrophage traits in cancer progression: a consequence of tumor cell fusion? Contrib Microbiol. 2006;13:138-55.
162. Pawelek JM. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol. 2005;6(12):988-93.
163. Rachkovsky M, Pawelek J. Acquired melanocyte stimulating hormone-inducible chemotaxis following macrophage fusion with Cloudman S91 melanoma cells. Cell Growth Differ. 1999;10(7):517-24.
164. Pawelek JM. Cancer-cell fusion with migratory bone-marrow-derived cells as an explanation for metastasis: new therapeutic paradigms. Future Oncol. 2008;4(4):449-52.
165. Pawelek JM, Chakraborty AK. The cancer cell-leukocyte fusion theory of metastasis. Adv Cancer Res. 2008;101:397-444.
166. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer. 2008;8(5):377-86.
167. Eriksson EE, Werr J, Guo Y, Thoren P, Lindbom L. Direct observations in vivo on the role of endothelial selectins and alpha(4) integrin in cytokine-induced leukocyte-endothelium interactions in the mouse aorta. Circ Res. 2000;86(5):526-33.
168. Konstantopoulos K, Thomas SN. Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng. 2009;11:177-202.
169. Vestweber D. Molecular mechanisms that control leukocyte extravasation through endothelial cell contacts. Ernst Schering Found Symp Proc. 2007;(3):151-67.
170. Vestweber D. Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol Rev. 2007;218:178-96.
171. Wiese G, Barthel SR, Dimitroff CJ. Analysis of physiologic E-selectin-mediated leukocyte rolling on microvascular endothelium. J Vis Exp. 2009;(24):1,009.
172. Lazova R, Chakraborty A, Pawelek JM. Leukocyte-cancer cell fusion: initiator of the warburg effect in malignancy? Adv Exp Med Biol. 2011;714:151-72.
173. Huysentruyt LC, Seyfried TN. Perspectives on the mesenchymal origin of metastatic cancer. Cancer Metastasis Rev. 2010;29(4):695-707.
174. Johansson CB, Youssef S, Koleckar K, Holbrook C, Doyonnas R, Corbel SY, Steinman L, Rossi FM, Blau HM. Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation. Nat Cell Biol. 2008;10(5):575-83.
175. Deng L, Chen N, Li Y, Zheng H, Lei Q. CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochim Biophys Acta. 2010;1806(1):42-9.
176. Chakraborty AK, Sodi S, Rachkovsky M, Kolesnikova N, Platt JT, Bolognia JL, Pawelek JM. A spontaneous murine melanoma lung metastasis comprised of host x tumor hybrids. Cancer Res. 2000;60(9):2,512-19.
177. Chakraborty A, Lazova R, Davies S, Backvall H, Ponten F, Brash D, Pawelek J. Donor DNA in a renal cell carcinoma metastasis from a bone marrow transplant recipient. Bone Marrow Transplant. 2004;34(2):183-86.
178. Yilmaz Y, Lazova R, Qumsiyeh M, Cooper D, Pawelek J. Donor Y chromosome in renal carcinoma cells of a female BMT recipient: visualization of putative BMT-tumor hybrids by FISH. Bone Marrow Transplant. 2005;35(10):1,021-4.
179. Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A, Foglieni B, Spreafico M, Guerneri S, Baccarin M, Bertolini F, Rossi G, Mazzaferro V, Cadamuro M, Maggioni M, Agnelli L, Rebulla P, Prati D, Porretti L. Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS One. 2011;6(6):e21369.
180. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from bone marrow-derived cells. Science. 2004;306(5701):1568-71.
181. Powell AE, Anderson EC, Davies PS, Silk AD, Pelz C, Impey S, Wong MH. Fusion between intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res. 2011;71(4):1497-505.
182. Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmbhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, Butterfield YS, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Jones SJ, Hirst M, Marra MA, Maher CA, Chinnaiyan AM, Sahinalp SC, Gleave ME, Volik SV, Collins CC. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol. 2012;227(1):53-61.
183. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels S, Cristofanilli M. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist. 2009;14(12):1182-1188.
184. Boimel PJ, Smirnova T, Zhou ZN, Wyckoff J, Park H, Coniglio SJ, Qian BZ, Stanley ER, Cox D, Pollard JW, Muller WJ, Condeelis J, Segall JE. Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res. 2012;14(1):R23.
185. Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther. 2011;11(4):621-30.
186. D'Alterio C, Barbieri A, Portella L, Palma G, Polimeno M, Riccio A, Ierano C, Franco R, Scognamiglio G, Bryce J, Luciano A, Rea D, Arra C, Scala S. Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol Immunother. 2012;61(10):1,713-20.
187. Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res. 2009;15(9):2,962-70.
188. Gassmann P, Haier J, Schluter K, Domikowsky B, Wendel C, Wiesner U, Kubitza R, Engers R, Schneider SW, Homey B, Muller A. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia. 2009;11(7):651-61.
189. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65(3):967-71.
190. Mukhopadhyay KD, Bandyopadhyay A, Chang TT, Elkahloun AG, Cornell JE, Yang J, Goins BA, Yeh IT, Sun LZ. Isolation and characterization of a metastatic hybrid cell line generated by ER negative and ER positive breast cancer cells in mouse bone marrow. PLoS One. 2011;6(6):e20473.
191. Schuettpelz LG, Link DC. Niche competition and cancer metastasis to bone. J Clin Invest. 2011;121(4):1,253-55.
192. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64(23):8,604-12.
193. Uchida D, Onoue T, Kuribayashi N, Tomizuka Y, Tamatani T, Nagai H, Miyamoto Y. Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur J Cancer. 2011;47(3):452-9.
194. Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, Tan YS, He J. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer. 2009;9:176-87.
195. Ying J, Xu Q, Zhang G, Liu B, Zhu L. The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Med Oncol. 2012;29(3):1,716-22.
196. Zlotnik A. Involvement of chemokine receptors in organ-specific metastasis. Contrib Microbiol.2006;13:191-9.
197. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597-606.
198. Zhang N, Zhang WJ, Cai HQ, Liu HL, Peng L, Li CH, Ye LY, Xu SQ, Yang ZH, Lou JN. Platelet adhesion and fusion to endothelial cell facilitate the metastasis of tumor cell in hypoxia-reoxygenation condition. Clin Exp Metastasis. 2011;28(1):1-12.
199. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010;107(50):21,677-82.
200. Hart IR, Talmadge JE, Fidler IJ. Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res. 1981;41(4):1,281-7.
201. Garcia-Olmo DC, Picazo MG, Garcia-Olmo D. Transformation of non-tumor host cells during tumor progression: theories and evidence. Expert Opin Biol Ther. 2012;12(Supplement 1):S199-207.
202. Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL, Holmgren L. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci U S A. 2001;98(11):6,407-11.
203. Holmgren L, Szeles A, Rajnavolgyi E, Folkman J, Klein G, Ernberg I, Falk KI. Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood. 1999;93(11):3,956-63.
204. Antonyak MA, Li B, Boroughs LK, Johnson JL, Druso JE, Bryant KL, Holowka DA, Cerione RA. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci U S A. 2011;108(12):4,852-7.
205. Fox AS, Duggleby WF, Gelbart WM, Yoon SB. DNA-induced transformation in Drosophila: evidence for transmission without integration. Proc Natl Acad Sci U S A. 1970;67(4):1,834-8.
206. Fox AS, Yoon SB, Gelbart WM. DNA-induced transformation in Drosophila: genetic analysis of transformed stocks. Proc Natl Acad Sci U S A. 1971;68(2):342-6.
207. Goldenberg DM. Horizontal transmission of malignancy by cell-cell fusion. Expert Opin Biol Ther. 2012;12(Supplement 1):S133-9.
208. Wolbach SB. The Filterable Viruses, a Summary. J Med Res. 1912;27(1):1-25.
209. Stanley WM. Relationships, established and prospective, between viruses and cancer. Ann N Y Acad Sci. 1958;71(6):1,100-13.
210. Anonymous. Viruses and cancer. Br Med J. 1925;2(3369):174-6.
211. Anonymous. The theory of the cancer virus. Br Med J. 1926;1(3411):879.
212. Anonymous. Chemical agents and viruses in cancer. Br Med J. 1939;2(4107):651-2.
213. Horsfall FL Jr. Current concepts of cancer. Can Med Assoc J. 1963;89:1,224-9.
214. Okada Y, Hosokawa Y. Isolation of a new variant of HVJ showing low cell fusion activity. Biken J. 1961;4:217-20.
215. Knowles B, Steplewski Z, Swetly P, Barbanti-Brodano G, Koprowski H. Cell hybridization and tumor viruses. Wistar Inst Symp Monogr. 1969;9:37-49.
216. Takagi N, Aya T, Kato H, Sandberg AA. Relation of virus-induce cell fusion and chromosome pulverization to mitotic events. J Natl Cancer Inst. 1969;43(2):335-47.
217. Heneen WK, Nichols WW, Levan A, Norrby E. Polykaryocytosis and mitosis in a human cell line after treatment with measles virus. Hereditas. 1970;64(1):53-84.
218. Marin G. Somatic cell hybridization and problems of viral oncogenesis. In Vitro. 1970;5:94-108.
219. Poste G. Virus-induced polykaryocytosis and the mechanism of cell fusion. Adv Virus Res. 1970;16:303-56.
220. Ikeuchi T, Sandberg AA. Chromosome pulverization in virus-induced heterokaryons of mammalian cells from different species. J Natl Cancer Inst. 1970;45(5):951-63.
221. MacLaine NJ, Hupp TR. How phosphorylation controls p53. Cell Cycle. 2011;10(6):916-21.
222. Maclaine NJ, Hupp TR. The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany NY). 2009;1(5):490-502.
223. Incassati A, Patel D, McCance DJ. Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6. Oncogene. 2006;25(17):2,444-51.
224. Marshall WL, Yim C, Gustafson E, Graf T, Sage DR, Hanify K, Williams L, Fingeroth J, Finberg RW. Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak. J Virol. 1999;73(6):5,181-5.
225. Parris GE. The role of viruses in cell fusion and its importance to evolution, invasion and metastasis of cancer clones. Med Hypotheses. 2005;64(5):1,011-14.
226. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 1999;400(6743):464-68.
227. Zuo J, Thomas WA, Haigh TA, Fitzsimmons L, Long HM, Hislop AD, Taylor GS, Rowe M. Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. PLoS Pathog. 2011;7(12):e1002455.
228. Gallico E. The influence of viruses on the evolution of some malignant tumors. J Natl Med Assoc. 1955;47(3):158-61.
229. Moore AE. The oncolytic viruses. Prog Exp Tumor Res. 1960;1:411-39.
230. Moore AE. Viruses with oncolytic properties and their adaptation to tumors. Ann N Y Acad Sci. 1952;54(6):945-52.
231. Pollard M, Bussell RH. Oncolytic effect of viruses in tissue cultures. Proc Soc Exp Biol Med.1952;80(4):574-8.
232. Tedcastle A, Cawood R, Di Y, Fisher KD, Seymour LW. Virotherapy--cancer targeted pharmacology. Drug Discov Today. 2012;17(5-6):215-20.
233. Minkler JL, Gofman JW, Tandy RK. A specific common chromosomal pathway for the origin of human malignancy. II. Br J Cancer. 1970;24(4):726-40.
234. Bender MA, Kastenbaum MA, Lever CS. Chromosome 16: a specific chromosomal pathway for the origin of human malignancy? Br J Cancer. 1972;26(1):34-42.
235. Duelli D, Lazebnik Y. Cell-to-cell fusion as a link between viruses and cancer. Nat Rev Cancer. 2007;7(12):968-76.
236. Duelli DM, Hearn S, Myers MP, Lazebnik Y. A primate virus generates transformed human cells by fusion. J Cell Biol. 2005;171(3):493-503.
237. Duelli DM, Padilla-Nash HM, Berman D, Murphy KM, Ried T, Lazebnik Y. A virus causes cancer by inducing massive chromosomal instability through cell fusion. Curr Biol 2007, 17(5):431-7.
238. Duelli D, Lazebnik Y. Cell fusion: a hidden enemy? Cancer Cell. 2003;3(5):445-448.
239. Pawelek JM. Viewing malignant melanoma cells as macrophage-tumor hybrids. Cell Adh Migr. 2007;1(1):2-6.
240. Davies PS, Powell AE, Swain JR, Wong MH. Inflammation and proliferation act together to mediate intestinal cell fusion. PLoS One. 2009;4(8):e6530.
241. Dittmar T, Nagler C, Schwitalla S, Reith G, Niggemann B, Zanker KS. Recurrence cancer stem cells--made by cell fusion? Med Hypotheses. 2009;73(4):542-7.
242. Dittmar T, Schwitalla S, Seidel J, Haverkampf S, Reith G, Meyer-Staeckling S, Brandt BH, Niggemann B, Zanker KS. Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells. Clin Exp Metastasis. 2011;28(1):75-90.
243. Islam MQ, Meirelles Lda S, Nardi NB, Magnusson P, Islam K. Polyethylene glycol-mediated fusion between primary mouse mesenchymal stem cells and mouse fibroblasts generates hybrid cells with increased proliferation and altered differentiation. Stem Cells Dev. 2006;15(6):905-19.
244. Chen KA, Laywell ED, Marshall G, Walton N, Zheng T, Steindler DA. Fusion of neural stem cells in culture. Exp Neurol. 2006;198(1):129-35.
245. Gao P, Zheng J. Oncogenic virus-mediated cell fusion: new insights into initiation and progression of oncogenic viruses--related cancers. Cancer Lett. 2011;303(1):1-8.
246. Lu X, Kang Y. Cell fusion as a hidden force in tumor progression. Cancer Res. 2009;69(22):8,536-9.
247. Storchova Z, Kuffer C. The consequences of tetraploidy and aneuploidy. J Cell Sci. 2008;121(Pt 23):3,859-66.
248. Wu XZ, Chen D, Xie GR. Bone marrow-derived cells: roles in solid tumor. Minireview. Neoplasma. 2007;54(1):1-6.
249. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24(3):413-20.
250. Nicholas J. Human herpesvirus 8-encoded proteins with potential roles in virus-associated neoplasia. Front Biosci. 2007;12:265-81.
251. Hu L, Ceresa BP. Characterization of the plasma membrane localization and orientation of HPV16 E5 for cell-cell fusion. Virology. 2009;393(1):135-43.
252. Hu L, Plafker K, Vorozhko V, Zuna RE, Hanigan MH, Gorbsky GJ, Plafker SM, Angeletti PC, Ceresa BP. Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion. Virology. 2009;384(1):125-34.
253. Gao P, Zheng J. High-risk HPV E5-induced cell fusion: a critical initiating event in the early stage of HPV-associated cervical cancer. Virol J. 2010;7:238.
254. Hu L, Potapova TA, Li S, Rankin S, Gorbsky GJ, Angeletti PC, Ceresa BP. Expression of HPV16 E5 produces enlarged nuclei and polyploidy through endoreplication. Virology. 2010;405(2):342-51.
255. Koopman LA, Szuhai K, van Eendenburg JD, Bezrookove V, Kenter GG, Schuuring E, Tanke H, Fleuren GJ. Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res. 1999;59(21):5,615-24.
256. Parris GE. 2-deoxy-D-glucose as a potential drug against fusogenic viruses including HIV. Med Hypotheses. 2008;70(4):776-82.
257. Parris GE. Anti-fusion drug candidates that may have beneficial effects against cancer, virus infections and autoimmune disorders. Med Hypotheses. 2008;70(2):463.
258. Helming L, Gordon S. The molecular basis of macrophage fusion. Immunobiology. 2007;212(9-10):785-93.
259. Helming L, Gordon S. Molecular mediators of macrophage fusion. Trends Cell Biol. 2009;19(10):514-22.